Triplet Therapy Ups Progression-Free Survival in Advanced Kidney Cancer
MONDAY, Sept. 26, 2022 -- Triplet therapy of cabozantinib + nivolumab + ipilimumab significantly improves progression-free survival (PFS) compared with placebo + nivolumab + ipilimumab for patients with previously untreated advanced renal cell...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Urology & Nephrology | Yervoy